Biotech News
Related news
XGNExagen2026-07-21 13:00 EST
Exagen to Announce Second Quarter Financial Results on August 4, 2026
XGNExagen2026-08-04 12:00 EST
Exagen Inc. Reports Second Quarter 2026 Financial Results
OSUROraSure Technologies, Inc.2026-07-22 20:10 EST
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
IMVTImmunovant2026-07-23 20:05 EST
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
ANABAnaptysBio, Inc.2026-09-21 20:15 EST
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
HCWBHCW Biologics2026-08-14 19:15 EST
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
SERASera Prognostics2026-08-12 20:05 EST
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
SNGXSOLIGENIX2026-08-07 11:30 EST
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
GPCRStructure Therapeutics2026-08-06 20:05 EST
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Exagen
Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...
Recent company news
XGNExagen2026-08-04 12:00 EST
Exagen Inc. Reports Second Quarter 2026 Financial Results
XGNExagen2026-07-28 13:00 EST
Exagen Inc. to Participate in Upcoming Investor Conference
XGNExagen2026-07-21 13:00 EST
Exagen to Announce Second Quarter Financial Results on August 4, 2026
XGNExagen2026-06-01 13:00 EST
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
XGNExagen2026-05-11 12:00 EST
Exagen Inc. Reports First Quarter 2026 Results
Stock data
- Close
- 8.19 USD
- Market cap
- 116.45M USD
- Exchange
- NASDAQ
- Sector
- MedTech
- Location
- United States
